Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 4 - The Untold Story

GSK’s boss Emma Walmsley to step down after eight-year tenure

Dame Emma was the first woman to run a major pharmaceutical company when she became chief executive in 2017.

Evening Standard

GSK’s Emma Walmsley to step down as chief executive after eight years

GSK’s Emma Walmsley to step down as chief executive after eight years

Chief commercial officer Luke Miels to take over as CEO at Britain’s second-biggest drugmaker

The Guardian - UK

FTSE 100 Live 29 September: Index nears record, GSK shares rise on CEO change

FTSE 100 Live 29 September: Index nears record, GSK shares rise on CEO change

GSK chief executive Emma Walmsley is to step down after more than eight years running the pharmaceuticals giant.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Brighter US outlook fires up European stocks

The FTSE 100 index closed up 70.85 points, or 0.8%, at 9,284.83.

Evening Standard

Trump Administration Backs Leucovorin for Autism — How It Works, the Science Behind It and Its Effectiveness

The Trump administration has backed the use of leucovorin, a folate-based drug, for autism treatment. Here's what the science says, how it works, and why experts are divided on its effectiveness.

International Business Times UK

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

inkl

Read news from The Economist, FT, and more,
with one subscription

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years

GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.

FTSE 100 Live 17 September: Food prices blow, Barratt Redrow flags Budget delay risk

FTSE 100 Live 17 September: Food prices blow, Barratt Redrow flags Budget delay risk

The UK’s annual rate of inflation has stayed at the highest level since January 2024.

Evening Standard

UK set on resolving standoff with big pharma, science minister says

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

The Guardian - UK

Big pharma firms have paused nearly £2bn in UK investments this year

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots

Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, just days before it reconvenes to vote on COVID-19 shots and other routine pediatric vaccine recommendations.

China pharma deals threaten U.S. biotech

China pharma deals threaten U.S. biotech

The strategy comes as China has become a powerhouse in AI, chemistry and other areas.

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

Get all your
news in one place.

100's of premium titles.
One news app.

Shingles vaccine could lower risk of heart attack and stroke, study finds

Adults vaccinated against shingles had an 18 per cent lower risk of serious heart problems, the analysis found.

Evening Standard

FTSE 100 edges down despite hopes of end to Russia-Ukraine war

Evening Standard

GSK to be paid up to £370 million after patent row settles in US

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.

Evening Standard

FTSE 100 ends flat ahead of likely US rate hold

The FTSE 100 index closed up just 0.62 of a point at 9,136.94.

Get all your
news in one place.

100's of premium titles.
One news app.

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance.

The Independent UK

Business news live: FTSE 100 reaction as HSBC sees profits drop, Nationwide launches benefits line

Stock market news and latest business and finance updates from Wednesday

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE:GSK) on Monday to develop up to 12 medicines.

GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data

The US Food and Drug Administration (FDA) on Wednesday extended the review period for the Biologics License Application (BLA) for GSK plc’s (NYSE:GSK) Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy.

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations.

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults

On Monday, the U.S. Food and Drug Administration (FDA) agreed to review GSK plc’s (NYSE:GSK) application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk.

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer.

1 … 3 4 5 6

People

195,015 stories

Robert F. Kennedy Jr

Elizabeth Warren

Patrick Vallance

Robert Kennedy, Jr.

Charles Williams

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Supreme Court

the Trump Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

383,846 stories

140,952 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play